NF-κB cellular and molecular regulatory mechanisms and pathways: Therapeutic pattern or pseudoregulation?

Cellular Immunology

Volumn 271, Issue 1, 2011, Pages 5-14

  Haddad, John J ^a,b   Abdel Karim, Nisreen E ^a  

^a BEIRUT ARAB UNIVERSITY   (Lebanon)

^b Faculty of Medicine   (United States)

Author keywords

Decoy; Inhibitor; NF B; Oligonucleotides; Pseudoregulation; Therapy

Indexed keywords

15 DEOXYSPERGUALIN; 4 (2 AMINOETHYL)BENZENESULFONYL FLUORIDE; ALLOPURINOL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASTAXANTHIN; BENIDIPINE; BORTEZOMIB; DEFEROXAMINE; DENOSUMAB; DILAZEP; DIPHENHYDRAMINE; DISULFIRAM; DITHIOCARBAMIC ACID; DOXAZOSIN; FENOFIBRIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATURAL PRODUCT; NORPHENAZONE; OLMESARTAN; POLYLYSINE; ROTENONE; SALINOSPORAMIDE A; STAUROSPORINE; TACROLIMUS; TAXIFOLIN; TEMPOL; THIONEINE; TRANSCRIPTION FACTOR;

APOPTOSIS; DRUG EFFICACY; DRUG MECHANISM; GENE CONTROL; GRAFT REJECTION; HEPATITIS; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; NEOPLASM; NEUROBIOLOGY; NOCICEPTION; PRIORITY JOURNAL; REVIEW; TREATMENT CONTRAINDICATION; VIRUS INFECTION;

ANIMALS; APOPTOSIS; HUMANS; INFLAMMATION; MODELS, IMMUNOLOGICAL; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; SIGNAL TRANSDUCTION;

EID: 80052374406     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.06.021     Document Type: Review

References (59)

1. Sen R., Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986, 46(5):705-716.
2. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 2000, 18:621-663.
3. Nabel G.J., Verma I.M. Proposed NF-κB/IκB family nomenclature. Genes Dev. 1993, 7(11):2063.
4. Ghosh S., May M.J., Kopp E.B. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16:225-260.
5. Fusco A.J., Huang D.B., Miller D., Wang V.Y., Vu D., Ghosh G. NF-kappaB p52:RelB heterodimer recognizes two classes of kappaB sites with two distinct modes. EMBO Rep. 2009, 10(2):152-159.
6. Gilmore T.D. Introduction to NF-κB: players, pathways, perspectives. Oncogene 2006, 25(51):6680-6684.
7. Brasier A.R. The NF-κB regulatory network. Cardiovasc. Toxicol. 2006, 6(2):111-130.
8. Perkins N.D. Integrating cell-signalling pathways with NF-κB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8(1):49-62.
9. Gilmore T.D. The Rel/NF-κB signal transduction pathway: introduction. Oncogene 1999, 18(49):6842-6844.
10. Tian B., Brasier A.R. Identification of a nuclear factor κ B-dependent gene network. Recent Prog. Horm. Res. 2003, 58:95-130.
11. Lieb W., Gona P., Larson M.G., Massaro J.M., Lipinska I., Keaney J.F., Rong J., Corey D., Hoffmann U., Fox C.S., Vasan R.S., Benjamin E.J., O'Donnell C.J., Kathiresan S. Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality. Arterioscler. Thromb. Vasc. Biol. 2010, 30(9):1849-1854.
12. Cabrini G., Bezzerri V., Mancini I., Nicolis E., Dechecchi M.C., Tamanini A., Lampronti I., Piccagli L., Bianchi N., Borgatti M., Gambari R. Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: decoy oligonucleotides and low-molecular weight compounds. Curr. Med. Chem. 2010, 17(35):4392-4404.
13. De Stefano D., De Rosa G., Carnuccio R. NFkappaB decoy oligonucleotides. Curr. Opin. Mol. Ther. 2010 Apr, 12(2):203-213.
14. Hamdy N.A. Denosumab: RANKL inhibition in the management of bone loss. Drugs Today (Barc). 2008, 44(1):7-21.
15. Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. Synapse 2000, 35(2):151-159.
16. Senftleben U., Cao Y., Xiao G., Greten F.R., Krähn G., Bonizzi G., Chen Y., Hu Y., Fong A., Sun S.C., Karin M. Activation by IKKalpha of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001, 293(5534):1495-1499.
17. Waterhouse R.M., Kriventseva E.V., Meister S., Xi Z., Alvarez K.S., Bartholomay L.C., Barillas-Mury C., Bian G., Blandin S., Christensen B.M., Dong Y., Jiang H., Kanost M.R., Koutsos A.C., Levashina E.A., Li J., Ligoxygakis P., Maccallum R.M., Mayhew G.F., Mendes A., Michel K., Osta M.A., Paskewitz S., Shin S.W., Vlachou D., Wang L., Wei W., Zheng L., Zou Z., Severson D.W., Raikhel A.S., Kafatos F.C., Dimopoulos G., Zdobnov E.M., Christophides G.K. Evolutionary dynamics of immune-related genes and pathways in disease-vector mosquitoes. Science 2007, 316(5832):1738-1743.
18. Doyle S.L., O'Neill L.A. Toll-like receptors: from the discovery of NF-κB to new insights into transcriptional regulations in innate immunity. Biochem. Pharmacol. 2006, 72(9):1102-1113.
19. Hayden M.S., West A.P., Ghosh S. NF-κB and the immune response. Oncogene 2006, 25(51):6758-6780.
20. Haddad J.J., Olver R.E., Land S.C. Antioxidant/pro-oxidant equilibrium regulates HIF-1alpha and NF-kappa B redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J. Biol. Chem. 2000, 275(28):21130-21139.
21. Li Q., Verma I.M. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2002, 2(10):725-734.
22. Hiscott J., Kwon H., Génin P. Hostile takeovers: viral appropriation of the NF-κB pathway. J. Clin. Invest. 2001, 107(2):143-151.
23. Adkins I., Schulz S., Borgmann S., Autenrieth I.B., Gröbner S. Differential roles of Yersinia outer protein P-mediated inhibition of nuclear factor-κB in the induction of cell death in dendritic cells and macrophages. J. Med. Microbiol. 2008, 57(Pt 2):139-144.
24. Nelson D.E., Ihekwaba A.E., Elliott M., Johnson J.R., Gibney C.A., Foreman B.E., Nelson G., See V., Horton C.A., Spiller D.G., Edwards S.W., McDowell H.P., Unitt J.F., Sullivan E., Grimley R., Benson N., Broomhead D., Kell D.B., White M.R. Oscillations in NF-κB signaling control the dynamics of gene expression. Science 2004, 306(5696):704-708.
25. Bonizzi G., Bebien M., Otero D.C., Johnson-Vroom K.E., Cao Y., Vu D., Jegga A.G., Aronow B.J., Ghosh G., Rickert R.C., Karin M. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J. 2004, 23(21):4202-4210.
26. Basak S., Shih V.F., Hoffmann A. Generation and activation of multiple dimeric transcription factors within the NF-kappaB signaling system. Mol. Cell Biol. 2008, 28(10):3139-3150.
27. Karin M. The IκB kinase - a bridge between inflammation and cancer. Cell Res. 2008, 18(3):334-342.
28. Mantovani A., Marchesi F., Portal C., Allavena P., Sica A. Linking inflammation reactions to cancer: novel targets for therapeutic strategies. Adv. Exp. Med. Biol. 2008, 610:112-127.
29. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., Kowalczyk D., Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. I. Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-alpha) biosynthesis in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 2002, 300(2):559-566.
30. Haddad J.J., Land S.C., Tarnow-Mordi W.O., Zembala M., Kowalczyk D., Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-kappaB/nuclear factor-kappaB-sensitive pathway in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 2002, 300(2):567-576.
31. Bours V., Franzoso G., Azarenko V., Park S., Kanno T., Brown K., Siebenlist U. The oncoprotein Bcl-3 directly transactivates through κ B motifs via association with DNA-binding p50B homodimers. Cell 1993, 72(5):729-739.
32. Jacobs M.D., Harrison S.C. Structure of an IκBalpha/NF-κB complex. Cell 1998, 95(6):749-758.
33. Basak S., Kim H., Kearns J.D., Tergaonkar V., O'dea E., Werner S.L., Benedict C.A., Ware C.F., Ghosh G., Verma I.M., Hoffmann A. A fourth IκB protein within the NF-κB signaling module. Cell 2007, 128(2):369-381.
34. Dobrzanski P., Ryseck R.P., Bravo R. Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100. Oncogene 1995, 10(5):1003-1007.
35. Lo J.C., Basak S., James E.S., Quiambo R.S., Kinsella M.C., Alegre M.L., Weih F., Franzoso G., Hoffmann A., Fu Y.X. Coordination between NF-κB family members p50 and p52 is essential for mediating LTbetaR signals in the development and organization of secondary lymphoid tissues. Blood 2006, 107(3):1048-1055.
36. Venuraju S.M., Yerramasu A., Corder R., Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J. Am. Coll. Cardiol. 2010, 55(19):2049-2061.
37. Song X.Q., Lv L.X., Li W.Q., Hao Y.H., Zhao J.P. The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia. Biol. Psychiatry 2009, 65(6):481-488.
38. Massa P.T., Aleyasin H., Park D.S., Mao X., Barger S.W. NFκB in neurons? The uncertainty principle in neurobiology. J. Neurochem. 2006, 97(3):607-618.
39. Livolsi A., Busuttil V., Imbert V., Abraham R.T., Peyron J.F. Tyrosine phosphorylation-dependent activation of NF-κB. Requirement for p56 LCK and ZAP-70 protein tyrosine kinases. Eur. J. Biochem. 2001, 268(5):1508-1515.
40. Sheikh M.S., Huang Y. Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2003, 2(6):550-552.
41. Escárcega R.O., Fuentes-Alexandro S., García-Carrasco M., Gatica A., Zamora A. The transcription factor nuclear factor-κB and cancer. Clinical Oncology(Royal College of Radiologists (Great Britain)) 2007, 19(2):154-161.
42. Garg A., Aggarwal B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16(6):1053-1068.
43. Sethi G., Sung B., Aggarwal B.B. Nuclear factor-kappaB activation: from bench to bedside. Exp. Biol. Med. (Maywood) 2008, 233(1):21-31.
44. Vos I., Govers R., Grone H.-J., Kleij L., Schurink M., de Weger R., Goldschmeding R., Rabelink T.J. NF-kB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J. 2000, 14:815-822.
45. Kimura S., Egashira K., Chen L., Nakano K., Iwata E., Miyagawa M., Tsujimoto H., Hara K., Morishita R., Sueishi K., Tominaga R., Sunagawa K. Nanoparticle-mediated delivery of nuclear factor kappaB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 2009, 53(5):877-883.
46. Suzuki M., Inoue G., Gemba T., Watanabe T., Ito T., Koshi T., Yamauchi K., Yamashita M., Orita S., Eguchi Y., Ochiai N., Kishida S., Takaso M., Aoki Y., Takahashi K., Ohtori S. Nuclear factor-kappa B decoy suppresses nerve injury and improves mechanical allodynia and thermal hyperalgesia in a rat lumbar disc herniation model. Eur. Spine J. 2009, 18(7):1001-1007.
47. Sugao Y., Watanabe K., Higuchi Y., Kurihara R., Kawakami S., Hashida M., Katayama Y., Niidome T. NFkappaB decoy delivery using dendritic poly(l-lysine) for treatment of endotoxin-induced hepatitis in mice. Bioorg. Med. Chem. 2009, 17(14):4990-4995.
48. Jung K., Lee J.E., Kim H.Z., Kim H.M., Park B.S., Hwang S.I., Lee J.O., Kim S.C., Koh G.Y. Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis. PLoS One 2009, 4(10):e7403.
49. Buchanan K.D., Huang S.L., Kim H., McPherson D.D., MacDonald R.C. Encapsulation of NF-kappaB decoy oligonucleotides within echogenic liposomes and ultrasound-triggered release. J. Control. Release 2010, 141(2):193-198.
50. Sønder S.U., Saret S., Tang W., Sturdevant D.E., Porcella S.F., Siebenlist U. IL-17-induced NF-{kappa}B via CIKS/Act1: physiiologic significance and signaling mechansisms. J. Biol. Chem. 2011, 286(15):12881-12890.
51. Pikarsky E., Ben-Neriah Y. NF-κB inhibition: a double-edged sword in cancer?. Eur. J. Cancer 2006, 42(6):779-784.
52. Gambari R., Borgatti M., Bezzerri V., Nicolis E., Lampronti I., Dechecchi M.C., Mancini I., Tamanini A., Cabrini G. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras targeting nuclear factor kappa-B: inhibition of IL-8 gene expression in cystic fibrosis cells infected with Pseudomonas aeruginosa. Biochem. Pharmacol. 2010, 80(12):1887-1894.
53. Kim S.J., Park J.H., Kim K.H., Lee W.R., Lee S., Kwon O.C., Kim K.S., Park K.K. Effect of NF-κB decoy oligodeoxynucleotide on LPS/high-fat diet-induced atherosclerosis in an animal model. Basic Clin. Pharmacol. Toxicol. 2010, 107(6):925-930.
54. Li J.D., Peng Y., Peng X.Y., Li Q.L., Li Q. Suppression of nuclear factor-kappaB activity in Kupffer cells protects rat liver graft from ischemia-reperfusion injury. Transplant. Proc. 2010, 42(5):1582-1586.
55. Wang T., Li Q.H., Hao G.P., Zhai J. Antitumor activity of decoy oligodeoxynucleotides targeted to NF-kappaB in vitro and in vivo. Asian Pac. J. Cancer Prev. 2010, 11(1):193-200.
56. Tahara K., Samura S., Tsuji K., Yamamoto H., Tsukada Y., Bando Y., Tsujimoto H., Morishita R., Kawashima Y. Oral nuclear factor-κB decoy oligonucleotides delivery system with chitosan modified poly(d,l-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials 2011, 32(3):870-878.
57. Miyake T., Aoki M., Osako M.K., Shimamura M., Nakagami H., Morishita R. Systemic administration of ribbon-type decoy oligodeoxynucleotide against nuclear factor κB and ets prevents abdominal aortic aneurysm in rat model. Mol. Ther. 2011, 19(1):181-187.
58. Crinelli R., Carloni E., Menotta M., Giacomini E., Bianchi M., Ambrosi G., Giorgi L., Magnani M. Oxidized ultrashort nanotubes as carbon scaffolds for the construction of cell-penetrating NF-kappaB decoy molecules. ACS Nano 2010, 4(5):2791-2803.
59. Wijagkanalan W., Kawakami S., Higuchi Y., Yamashita F., Hashida M. Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation. J. Control. Release 2011, 149(1):42-50.